Metacam

Selected form

Meloxicam

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Cox Inhibitory, Nonsteroidal Anti-Inflammatory, Pain Reliever

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Osteoarthritis, Rheumatoid Arthritis, Spondylitis, Spondyloarthritis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metacam

What is Metacam? Definition and Pharmacological Classification

Property	Description
Active ingredient	Meloxicam (C14H13N3O4S2)
Form	Tablet, oral suspension, solution for injection
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Relief of pain and inflammation
Origin	Synthetic (Oxicam derivative)

Metacam is a globally recognized trade name for a medication whose therapeutic efficacy is attributed to the active ingredient, Meloxicam. This compound is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and belongs specifically to the oxicam group. This classification confirms the drug's primary function in interfering with the biochemical cascade that results in inflammation and associated pain. Meloxicam is clinically recognized for its ability to reduce joint inflammation and associated chronic discomfort, a conclusion supported by multiple pharmacological studies.

Composition, Origin, and Available Forms of Meloxicam

Meloxicam is a synthetic pharmaceutical compound that acts as a single-ingredient product, containing only the active substance and necessary excipients. The compound is chemically distinct from other major NSAID families. The medicine is manufactured for use across different patient and animal groups; for instance, the oral suspension form, often favored in pediatrics and veterinary practice due to ease of dosing, complements the standard tablet and sterile solution for injection.

What is the General Purpose of Metacam?

The general purpose of Metacam is to provide symptomatic relief by exhibiting sustained anti-inflammatory and analgesic effects. Meloxicam achieves this by targeting and reducing the body’s production of prostaglandins, which are key substances responsible for triggering swelling and pain signals. Because of its long plasma half-life, Meloxicam is convenient for once-daily administration, a distinctive feature that aids in the continuous management of chronic discomfort.

Regulatory References

NIH LiverTox: Meloxicam

What side effects are possible with Metacam?

Possible Side Effects and Safety Information

The official regulatory documentation for Metacam (Meloxicam) classifies and documents its possible adverse reactions and safety characteristics by system-organ class and frequency, adhering to standard regulatory frameworks.

Adverse Reaction Classification and Scope

Adverse effects are grouped into frequency tiers ranging from Common (e.g., dyspepsia, nausea, vomiting, abdominal pain, diarrhea) to Uncommon (e.g., anemia, headache, dizziness, edema, vertigo) and Rare (e.g., peptic ulceration, blurred vision, tinnitus, mood alterations). System-organ classes involved include Gastrointestinal disorders, Nervous system disorders, Blood and lymphatic system disorders, and Skin and subcutaneous tissue disorders.

Serious Adverse Reactions

Regulatory labeling specifies risks for potentially serious events. These include Serious Gastrointestinal Adverse Events, such as bleeding, ulceration, or perforation of the stomach or intestines. Another documented risk is for Serious Cardiovascular Thrombotic Events, including myocardial infarction (heart attack) and stroke. Rare but serious skin reactions, like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also listed.

Safety Patterns and Restrictions

The risk of cardiovascular thrombotic events may appear early in treatment and is documented to increase with the duration of use. Conversely, serious skin reactions are often reported to occur more frequently at the start of therapy. Specific safety considerations exist for certain populations: Older adults are documented to have a higher risk for serious GI adverse events and acute renal failure. The medicine is formally contraindicated in specific high-risk settings, such as for the treatment of peri-operative pain after coronary artery bypass graft (CABG) surgery, and in individuals with a history of allergic-type reactions to NSAIDs or severe organ impairment.

Overdose and Emergency Response

The official regulatory profile for a Metacam (Meloxicam) overdose is defined by the potential for systemic toxicity characteristic of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.

Documented Overdose Manifestations

Acute overdose may initially present with common gastrointestinal and central nervous system disturbances, including nausea, vomiting, lethargy, drowsiness, and epigastric pain. Gastrointestinal bleeding is also a documented sign.

Severe Outcomes and Required Actions

The official prescribing information states that severe poisoning may escalate into life-threatening complications, affecting major organ systems. These serious outcomes include acute renal failure, hepatic dysfunction, respiratory depression, convulsions, coma, cardiovascular collapse, and cardiac arrest.

Immediate medical attention is required upon any suspicion of overdose. Government guidance explicitly states that emergency services must be contacted immediately if the affected person has collapsed, is having a seizure, is experiencing trouble breathing, or cannot be awakened.

Because no specific antidote is known, overdose management is strictly symptomatic and supportive. This mandated care may involve hospital procedures such as gastric lavage, administration of activated charcoal to limit drug absorption, and the use of cholestyramine, which is cited in regulatory documents as accelerating the clearance of Meloxicam from the body.

Therapeutic Uses of Metacam

Metacam (Meloxicam) is applied across key therapeutic domains to manage symptoms related to inflammatory or irritative states. This medication is commonly used for managing conditions characterized by periods of heightened symptoms.

Managing Chronic Pain and Inflammation in Arthritis

The primary therapeutic use is in supporting patients with chronic conditions presenting with systemic or localized discomfort, including osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis in adults. It is also relevant for easing the symptoms of juvenile idiopathic arthritis (JIA) in children aged two years and older. It contributes to easing the overall symptom load, which supports patients during episodes of heightened discomfort.

Easing Functional Strain and Acute Pain Episodes

The medication helps address symptom clusters that interfere with daily functioning, specifically joint stiffness, swelling, and increased tenderness. It is applied when appropriate in clinical settings that involve unstable symptom patterns, such as managing moderate-to-severe pain following surgical procedures. The core benefit is providing supportive relief when symptoms become temporarily disruptive, which may assist with maintaining functional stability.

Quick Fact: Support for Symptoms of Joint Pain and Stiffness

Regulatory References

FDA-Approved Labeling (DailyMed)

Eligibility and Restrictions for Use

Official Eligibility Map for Metacam (Meloxicam)

Official regulatory documentation defines eligibility for Meloxicam based on age, existing medical conditions, and physiological status. Eligibility classifications such as "Contraindicated" or "Use Not Established" determine who may or may not use the medicine.

Classification	Status based on Regulatory Labeling
Populations Contraindicated	Must not use if there is a known hypersensitivity to meloxicam, aspirin, or other NSAIDs (e.g., aspirin-sensitive asthma). Use is also prohibited for pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and after 30 weeks gestation in pregnant women.
Age-Related Eligibility	Approved for adults (for Osteoarthritis and Rheumatoid Arthritis). Approved for children two years of age and older (specifically for Juvenile Idiopathic Arthritis - JIA). Use in children younger than two years is not established. Older adults ( 65 years) require increased caution.
Condition-Specific Restrictions	Avoid use in patients with severe heart failure or advanced renal disease not on dialysis. Dehydration or hypovolemia must be corrected before treatment begins. For women attempting to conceive, use is not recommended as it may impair fertility.

The regulatory profile explicitly defines the constraints for use, structuring the allowance for the medicine based on formal exclusion criteria rather than general safety summaries. Only populations matching the approved indications and regulatory safety profile are considered eligible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Meloxicam, the active ingredient in Metacam, has formally documented interaction patterns that are classified by regulatory authorities based on their mechanism and risk.

Interaction Domain	Relevant Agents and Effects Documented in Regulatory Sources
Pharmacodynamic Risk Reinforcement	Other NSAIDs (including analgesic-dose Aspirin) and Glucocorticosteroids increase the additive risk of serious gastrointestinal events and bleeding. Anticoagulants (e.g., Warfarin) and Antiplatelet Agents increase the risk of serious bleeding complications.
Renal/Electrolyte Interference	ACE-Inhibitors, ARBs, and Diuretics may have reduced efficacy; co-administration increases the risk of renal function deterioration, particularly in elderly or volume-depleted patients. Lithium and Methotrexate exposure and toxicity risk are increased due to Meloxicam reducing their renal clearance.
Metabolic/Clearance Modulation	The metabolism of Meloxicam primarily involves the CYP2C9 enzyme and, to a lesser extent, CYP3A4. Cholestyramine accelerates Meloxicam's elimination by disrupting its enterohepatic recirculation.
Substance-Specific Risk	Consumption of alcohol is documented to increase the risk of gastrointestinal bleeding and ulcer formation. Co-administration of the oral suspension with Sodium Polystyrene Sulfonate is restricted due to the documented risk of intestinal necrosis.

These official statements establish prohibitions (contraindications) and mandate careful oversight when combining Meloxicam with agents that affect hemostasis or renal function. The structure is based entirely on documented outcomes and restrictions found in governmental drug labels.

Mechanism of Action

Modulation of the Cyclooxygenase Enzyme System

Metacam (meloxicam) operates by targeting the Cyclooxygenase (COX) enzyme system in a reversible, inhibitory manner. The drug primarily acts by reducing the activity of the inducible form, COX-2, which is expressed at sites of tissue insult. This molecular interaction represents the earliest step of the mechanistic cascade, regulating the enzyme's function.

Suppression of Inflammatory Mediator Production

The primary mechanistic consequence of COX-2 inhibition is the suppression of the Eicosanoid Synthesis Pathway, which creates lipid mediators known as prostaglandins. These mediators are central components of the body's local and systemic inflammatory response pathways. By altering this pathway, the drug engages mechanisms that modulate heightened signaling within specific physiological pathways driven by excessive mediator activity.

Central and Peripheral Physiological Influence

The reduction in prostaglandins affects both peripheral tissues and the central nervous system. Peripherally, it reduces the chemical sensitization of nociceptors (pain receptors), while centrally, it influences the set point of the hypothalamic thermoregulatory center. This mechanism influences the status of signaling within the body's thermal pathways, which results in altered physiological responses related to prostaglandin presence.

Dosage and Administration Information

How to Use Metacam

Metacam (meloxicam) administration involves specific routes, standard doses, and frequency patterns. The medicine is primarily intended for once-daily administration, which is a defining feature of its use.

Official Administration and Dosage Patterns

The approved routes are oral (for tablets, capsules, and oral suspension) and intravenous (IV) (for solution for injection). The general principle for use is to employ the lowest effective dose for the shortest duration necessary.

Feature	Oral Administration Details
Standard Maximum Dose (Adult)	15 mg once daily
Standard Starting Dose (Adult)	Typically 7.5 mg once daily
Timing Relative to Meals	May be taken without regard to meals, or during a meal with water

Population-Specific Dosing Rules

Dose adjustments are utilized for specific patient groups. For example, the maximum oral dose for adults undergoing hemodialysis is restricted to 7.5 mg per day. For pediatric patients (age two and older) receiving the oral formulation for Juvenile Idiopathic Arthritis (JIA), the dose is calculated based on weight, with a maximum limit of 7.5 mg daily.

Procedural Administration Notes

Meloxicam preparations involve specific steps for proper use. The oral suspension is gently shaken before dispensing to ensure the dose is accurately measured. In the clinical setting, the intravenous formulation is administered rapidly as a bolus injection over approximately 15 seconds. If a dose is missed, the next dose is typically taken at the regularly scheduled time, and the dose should not be doubled.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Metacam (Meloxicam)

This section provides a transparent overview of the research that has studied the active ingredient Meloxicam (branded as Metacam), focusing on how symptoms were observed and measured in clinical trials. The evidence base consists primarily of controlled studies and systematic reviews, which regulators rely on to review the research patterns observed in the studies.

Research Evaluation in Osteoarthritis (OA)

Research exploring Meloxicam in conditions characterized by functional limitations, such as Osteoarthritis, utilized Randomized Controlled Trials (RCTs) and supporting meta-analyses. These studies monitored adult and older adult patients, often focusing on those with symptomatic OA of the knee or hip. The outcomes related to physical discomfort and daily functioning were the main axes of evaluation. Findings describe the patterns of measured outcomes that were observed across the study populations compared to control groups over defined time intervals. The results apply only to the populations studied and do not predict personal outcomes for every individual.

Research Evaluation in Rheumatoid Arthritis (RA)

Meloxicam was evaluated in studies examining the signs and symptoms of Rheumatoid Arthritis. The studies monitored outcomes capturing phases of heightened symptom activity, including the number of tender and swollen joints, and tracked standardized response criteria used to assess overall disease activity. Research describes the patterns observed for short-term symptom changes in RA and does not explore how the underlying course of the disease might be affected. Comparative evidence against some other anti-inflammatory agents is sometimes lacking across the body of research.

Evidence in Specific Patient Populations

Research examined the use of Meloxicam in children and adolescents with Juvenile Idiopathic Arthritis (JIA) through specific Randomized Controlled Trials. Subgroup findings are uncertain due to modest sample sizes. For older adults, pharmacokinetic studies show patterns related to a higher total concentration in older adult females compared to younger females; however, the reported patterns of symptoms were observed to be similar across these groups.

Research Gaps and Areas of Uncertainty

Research provides context but not individual predictions, and the evidence highlights what is known — and what is still uncertain. Long-term effects are not fully established across all populations, and the available data provides limited insight into long-term outcomes for patients with certain specific co-existing health conditions. The effectiveness of the oral Meloxicam formulation in rapid-onset, acute pain models is not well-characterized across the core studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Metacam (FAQ)

Q: How long does it take for Metacam to start working?

Studies and official information indicate that after an oral dose, the maximum concentration of Metacam (meloxicam) in the blood is typically reached within four to six hours. This measurement represents the time to the peak level the drug achieves in the body.

Q: What is the shelf-life of the oral suspension after I first open the bottle?

According to the official product information, the stability and shelf-life of the multi-dose oral suspension are generally limited to 6 months after the bottle is first opened. Information regarding the expiration date is also provided on the original packaging.

Q: Does Metacam interact with alcohol?

Regulatory documents state that consuming alcohol while using Metacam increases the documented risk of serious gastrointestinal events, such as bleeding and ulcer formation.

Q: How should I store Metacam tablets?

Official information advises that Metacam tablets should be kept at controlled room temperature, generally 20 C to 25 C. The medicine is to be kept protected from light and moisture in the original container. For some specific tablet formulations, storage below 25 C (77 F) is specified.

Q: What should I do if I take too much Metacam (overdose)?

Official documentation advises that if an overdose is suspected, emergency medical assistance, such as a poison control center or emergency room, should be contacted.

Q: Can I crush or split Metacam tablets to make them easier to swallow?

For certain types of Metacam tablets, such as orally disintegrating tablets, the official label explicitly instructs patients not to cut, crush, or chew the medication. Patients are instructed to follow the specific administration guidelines provided for their prescribed form of the medicine.

Q: Are there any food or herbal supplements that interact with Metacam?

Official documents focus on interactions with prescription drugs. The label does not specifically detail interactions with food or herbal supplements, but the overall safety profile should be discussed with a healthcare provider.

Q: What is the difference between Metacam and Mobic?

Mobic and Metacam are both proprietary brand names for medications. Official documents indicate that meloxicam is the therapeutic component (active ingredient) in both products.

Q: How should a pregnant woman or a woman who is breastfeeding use Metacam?

Regulatory documents state that use is prohibited in pregnant women after 30 weeks gestation. For breastfeeding women, official information indicates there is limited or no data available on the presence of the drug in human milk, and alternate agents may be preferred when nursing.

How should Metacam be stored and disposed of?

Storage and Disposal of Metacam

Official regulatory documents mandate specific conditions for storing Metacam (meloxicam) products to ensure stability.

Requirement	Official Statement (FDA/EMA)
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). Some tablets require storage below 25 C.
Handling/Protection	Keep in the original container, tightly closed, and protect from light and excess moisture.
Stability	Shelf-life after first opening the multi-dose oral suspension is generally limited to 6 months.
Child Safety	Keep out of the sight and reach of children and pets.

Disposal Mandates

Disposal of unused or expired Metacam must be conducted in accordance with local requirements. Regulatory guidelines prohibit disposal of the medicine via wastewater or household trash. Instead, patients are directed to use national collection systems or designated take-back schemes for safe environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.